BLA 125433 · Janssen Biotech
Simponi Aria
Golimumab · Injection · Tumor Necrosis Factor Blocker
OrphanLast checked: Nov 20, 2026Latest source record: Apr 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jul 18, 2013
Approved uses
7
Original approval plus efficacy supplements
Registered trials
110
40 Phase 3, 8 recruiting
FAERS reports
12,593
9,544 serious, 2,708 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA ( 5.1 ). Discontinue SIMPONI ARIA if a patient develops a serious infection or sepsis ( 5.1 ). Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA ( 5.1 ). Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ). Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member ( 5.2 ). SERIOUS INFECTIONS Patients treated with SIMPONI...
What it is approved for
From the label in effect Sep 9, 2025.
SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
Mechanism: Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα. This interaction prevents the binding of TNFα to its receptors, thereby inhibiting the biological activity of TNFα (a cytokine protein). There was no evidence of the golimumab antibody binding to other TNF superfamily ligands; in particular, the golimumab antibody did not bind or neutralize human lymphotoxin. Golimumab did not lyse human monocytes expressing transmembrane TNF in the presence of complement or effector cells. Elevated TNFα levels in the blood, synovium, and...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 1, 2021 Supplement 32 · Efficacy LetterLabel
- Sep 29, 2020 Supplement 30 · Efficacy OrphanLetter
- Sep 29, 2020 Supplement 31 · Efficacy LetterLabel
- Oct 20, 2017 Supplement 21 · Efficacy LetterLabel
- Oct 20, 2017 Supplement 20 · Efficacy LetterLabel
- Aug 5, 2015 Supplement 14 · Efficacy LabelReviewLetter
- Jul 18, 2013 Original approval ReviewLetterLabel
1 products under this application
- SIMPONI ARIA · GOLIMUMAB 50MG/4ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Golimumab" as an intervention, any sponsor and status, largest first.
- Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00975130 · 3,366 participants · Start Sep 2009 · Primary completion Aug 2011
Drug: SC golimumab; IV golimumab · For: Arthritis, Rheumatoid
- An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00488631 · 1,228 participants · Start Sep 2007 · Primary completion Oct 2011
Drug: Placebo; Golimumab 50 mg and 2 more · For: Colitis, Ulcerative
Sites: Birmingham, Alabama; Little Rock, Arkansas; Anaheim, California · 297 sites in all
- An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00487539 · 1,065 participants · Start Aug 2007 · Primary completion Oct 2010
Drug: Placebo; Golimumab 100 mg and 3 more · For: Colitis, Ulcerative
Sites: Birmingham, Alabama; Little Rock, Arkansas; Roseville, California · 200 sites in all
- COVID-19 VaccinE Response in Rheumatology PatientsPivotal-lookingCompleted
Jeffrey CurtisAcademic, hospital or other
NCT05080218 · 841 participants · Start Nov 15, 2021 · Primary completion Apr 4, 2024
Drug: Upadacitinib; Abatacept and 6 more · For: Rheumatoid Arthritis; Psoriatic Arthritis; Spondylarthritis
Sites: Birmingham, Alabama; Hoover, Alabama; Phoenix, Arizona · 8 sites in all
- Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic ArthritisPivotal-lookingCompleted
Bio-Thera SolutionsIndustry
NCT05046431 · 704 participants · Start May 6, 2021 · Primary completion Oct 6, 2023
Drug: BAT2506; EU Simponi · For: Psoriatic Arthritis
Sites: Chengdu, China
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05242471 · 703 participants · Start Jul 22, 2022 · Primary completion May 23, 2025
Drug: Guselkumab; Golimumab and 2 more · For: Crohn's Disease
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 456 sites in all
- Determination of the Optimal Treatment Target in Ulcerative ColitisPivotal-lookingCompleted
Alimentiv Inc.Academic, hospital or other
NCT04259138 · 672 participants · Start Feb 18, 2020 · Primary completion Apr 13, 2026
Drug: Treatment Algorithm A; Treatment Algorithm B and 1 more · For: Colitis, Ulcerative
Sites: Ypsilanti, Michigan; New York, New York; Asheville, North Carolina · 58 sites in all
- Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid ArthritisPivotal-lookingStatus unknown
CHU de Quebec-Universite LavalAcademic, hospital or other
NCT02242474 · 660 participants (planned) · Start Jul 2015 · Primary completion Oct 2019
Drug: Anti-TNF suspended perioperatively; Anti-TNFα continued perioperatively · For: Rheumatoid Arthritis
Sites: Québec, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,916
- off label use2,949
- pain2,949
- rheumatoid arthritis2,927
- fatigue2,768
- alopecia2,587
- rash2,513
- systemic lupus erythematosus2,509
- abdominal discomfort2,482
- pemphigus2,476
- glossodynia2,470
- hypersensitivity2,434
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 124 |
| 2010 | 170 |
| 2011 | 304 |
| 2012 | 243 |
| 2013 | 200 |
| 2014 | 124 |
| 2015 | 594 |
| 2016 | 405 |
| 2017 | 590 |
| 2018 | 752 |
| 2019 | 768 |
| 2020 | 775 |
| 2021 | 1,050 |
| 2022 | 1,243 |
| 2023 | 1,034 |
| 2024 | 1,785 |
| 2025 | 1,676 |
| 2026 | 756 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Simponi Aria (Golimumab)
2024 spending
$45.9M
Beneficiaries
1,596
6,219 claims
Per beneficiary
$28,755
$488.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,925,046 |
| 2021 | $23,709,395 |
| 2022 | $30,867,534 |
| 2023 | $38,842,776 |
| 2024 | $45,893,236 |
Part B: Simponi Aria (Golimumab) · HCPCS J1602
2024 spending
$330M
Beneficiaries
33,452
161,396 claims
Per beneficiary
$9,865
2024 ASP limit $11.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $359,695,134 |
| 2021 | $370,063,975 |
| 2022 | $374,047,499 |
| 2023 | $364,677,329 |
| 2024 | $329,994,823 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, et al. · Lancet Gastroenterol Hepatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS, Olivera PA, Danese S, et al. · Lancet Gastroenterol Hepatol 2022 · Systematic Review, Network Meta-Analysis
- Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions.
Shao J, Vetter M, Vermeulen A, et al. · Clin Pharmacol Ther 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T, Haller MJ, Steck AK, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.